5 protocols meet the specified criteria.
-
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
-
Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions
-
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
-
A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial
-
REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)